Kiniksa Pharmaceuticals International Financial Statements
NASDAQ: KNSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kiniksa Pharmaceuticals International revenue and earnings
In fiscal 2025, Kiniksa Pharmaceuticals International generated $677.6 million in revenue, up 60.1% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $59.0 million, for a net margin of 8.7% versus a median of -2.5% in the prior 5 years. Gross margin was 88.5% (up from 85.6%) and operating margin 11.4%.
Diluted earnings per share came in at $0.75.
Summary generated from market data by MetaCap's automated system. Methodology
Kiniksa Pharmaceuticals International income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 677.56M | 423.24M | 270.26M | 220.18M | 38.54M | — | — | — | — |
| Revenue growth (YoY) | +60.09% | +56.60% | +22.74% | +471.24% | — | — | — | — | — |
| Cost of Revenue | 77.67M | 60.91M | 33.41M | 22.89M | 9.10M | — | — | — | — |
| Gross Profit | 599.89M | 362.33M | 236.85M | 197.28M | 29.44M | — | — | — | — |
| Operating Expenses | 522.67M | 407.94M | 262.05M | 187.51M | 186.08M | 157.36M | 169.96M | 108.16M | 65.40M |
| Research & Development | 96.85M | 111.62M | 76.10M | 65.49M | 99.30M | 112.04M | 135.00M | 86.60M | 56.36M |
| Selling, General & Admin | 196.27M | 168.01M | 129.43M | 97.95M | 85.95M | 45.32M | 34.96M | — | — |
| Operating Income | 77.22M | -45.62M | -25.20M | 9.77M | -156.64M | -157.36M | -169.96M | -108.16M | -65.40M |
| Other Income (Expense) | 11.65M | 9.46M | 8.54M | 1.25M | 97.00K | 1.13M | — | — | — |
| Pretax Income | 88.87M | -36.15M | -16.65M | 11.03M | -156.54M | -156.23M | -163.91M | -103.44M | -64.87M |
| Income Tax | 29.86M | 7.04M | -30.74M | -172.34M | 1.39M | 5.15M | -2.05M | -214.00K | 2.00K |
| Net Income | 59.01M | -43.19M | 14.08M | 183.36M | -157.92M | -161.38M | -161.87M | -103.23M | -64.87M |
| Net Income growth (YoY) | — | -406.68% | -92.32% | — | — | — | — | — | — |
| EPS (Basic) | 0.80 | -0.60 | 0.20 | 2.64 | -2.30 | -2.61 | -2.99 | -3.49 | -35.85 |
| EPS (Diluted) | 0.75 | -0.60 | 0.20 | 2.60 | -2.30 | -2.61 | -2.99 | -3.49 | -35.85 |
| Shares Outstanding (Basic) | 74.20M | 71.42M | 70.06M | 69.38M | 68.58M | 61.84M | 54.05M | 29.55M | 1.81M |
| Shares Outstanding (Diluted) | 78.98M | 71.42M | 71.92M | 70.42M | 68.58M | 61.84M | 54.05M | 29.55M | 1.81M |
| EBITDA | 78.78M | -43.92M | -22.86M | 12.18M | -154.28M | -154.96M | -167.90M | -107.87M | -65.37M |
| Gross Margin | 88.54% | 85.61% | 87.64% | 89.60% | 76.39% | — | — | — | — |
| Operating Margin | 11.40% | -10.78% | -9.32% | 4.44% | -406.38% | — | — | — | — |
| Net Margin | 8.71% | -10.21% | 5.21% | 83.28% | -409.72% | — | — | — | — |
This table shows 9 annual periods of Kiniksa Pharmaceuticals International's income statement, from FY 2025 back to FY 2017, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow KNSA's reporting calendar. What is a income statement?